NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions in Denmark

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

128 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational study to assess the effectiveness and use of pregabalin (Lyrica) in the treatment of patients with peripheral neuropathic pain in real-life daily clinical practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.

NCT00219544

Neuropathic Pain

COMPLETED PHASE3

Primary Care Identification Of Patients With Chronic Neuropathic Low Back Pain Study

NCT01298466

Low Back Pain Neuralgia

WITHDRAWN PHASE4

Pregabalin Peripheral Neuropathic Pain Study

NCT00141219

Diabetic Neuropathies Neuralgia

COMPLETED PHASE3

Trial of Efficacy and Safety of Pregabalin in Subjects With Neuropathic Pain Associated With Lumbo-Sacral Radiculopathy

NCT00159705

Radiculopathy

COMPLETED PHASE3

Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain

NCT01455415

Painful Diabetic Peripheral Neuropathy

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

General practitioners and specialists participate in the study. When a subject, independently of the study and before consideration for observation in the study has been prescribed pregabalin for treatment of peripheral NeP, the subject can (before first dose of pregabalin is taken) be included in the observational program.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Neuropathic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with peripheral neuropathic pain treated with Lyrica

No intervention. Non-interventional study

Intervention Type OTHER

No intervention. Non-interventional study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention. Non-interventional study

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

pregabalin (Lyrica)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects aged 18 years or over.
* Subjects diagnosed with peripheral neuropathic pain.
* Subjects that independently of the study and before consideration for observation in the study have been prescribed pregabalin for treatment of peripheral neuropathic pain either.

1. for the first time ('first prescription patients') or
2. that have not used pregabalin within the previous 6 months but are prescribed pregabalin again ('re-treatment patients')
* Subjects that haven't taken the first dose of the prescribed pregabalin yet.

Exclusion Criteria

* Subjects not consenting to participate.
* Subjects that at study inclusion (baseline) are on treatment with pregabalin for generalized anxiety or epilepsy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No